Ozempic contains the active substance semaglutide. It helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease.
Ozempic is used:
• on its own – if your blood sugar is not controlled well enough by diet and exercise alone, and you cannot use metformin (another diabetes medicine) or
• with other medicines for diabetes – when they are not enough to control your blood sugar levels.
Ozempic contains the active substance semaglutide. It helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease.
Ozempic is used:
• on its own – if your blood sugar is not controlled well enough by diet and exercise alone, and you cannot use metformin (another diabetes medicine) or
• with other medicines for diabetes – when they are not enough to control your blood sugar levels.
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease.
Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Ozempic® is not indicated for use in patients with type 1 diabetes mellitus.
Important Safety Information Cont.
Contraindications
Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®.
Warnings and Precautions
Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart.
Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.
Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.
Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
Parlodel tablets contain the active ingredient bromocriptine, which belongs to a group of medicines
called dopamine agonists and prolactin inhibitors.
Parlodel tablets are used for:
Treatment of prolactinomas (a non-cancerous tumour of the pituitary gland in the brain).
Co-treatment of acromegaly with surgery or radiotherapy. Acromegaly is abnormal growth
caused by high levels of growth hormone.
Treatment of hyperprolactinaemia (abnormally high level of prolactin in the blood) in men
with hypogonadism (a low sperm count, lack of sex drive and inability to achieve an erection)
and/or galactorrhoea (unexplained milk secretion).
Treatment of hyperprolactinaemia (abnormally high level of prolactin in the blood) in women
with hypogonadism (infrequent periods, hot flushes, vaginal dryness), irregular periods,
infertility and/or galactorrhoea (unexplained milk secretion).
To prevent lactation (milk production) for medical reasons.
Stopping breast milk production for medical reasons only, and when you and your doctor have
decided that it is necessary. Bromocriptine should not be routinely used to stop breast milk
production. It should also not be used to relieve symptoms of painful breast engorgement after
giving birth if these can be adequately treated with non-medical means (such as firm breast
support, ice application) and or a painkiller.
DUODART is used to in men with benign prostatic hyperplasia (BPH).
BPH is a non-cancerousenlargement of the prostate gland which is located in the lowerportion of the urinary bladder surrounding the urethra (urine carrying tube).In menwith BPH, the prostate gland becomes large enough to squeeze the urine tube runningthrough it. If this tube is squeezed it narrows, making it more difficult to pass urine.
***Prescription Only Medicine Each film-coated tablet contains amoxicillin trihydrate equivalent to 500 mg amoxicillin and potassium clavulanate equivalent to 125 mg of clavulanic acid. Film-coated tablet White to off-white, oval shaped tablet debossed with ‘AC’ and a score line on one side. The score line is only to facilitate breaking for ease of swallowing and […]